Skip to main content
. Author manuscript; available in PMC: 2021 Apr 9.
Published in final edited form as: Leukemia. 2015 Nov 5;30(4):789–799. doi: 10.1038/leu.2015.308

Figure 8. Summary of PRMT5 activity and inhibition in AML.

Figure 8.

PRMT5 can suppress miR-29b expression in part by methylating histone H4R3 present at the promoter region of the miR. Low miR-29b levels leads to an increase in Sp1 protein levels and in turn elevated transcriptional activities of Sp1 at FLT3 promoter. This event ultimately can result in enhanced cell survival and growth. Our data also suggest that PRMT5 may also directly influence FLT3 expression by binding Sp1 at the promoter region of FLT3 and altering the levels of symmetrically dimethylated H3R8 mark at this locus. Inhibition of PRMT5 can block PRMT5 inhibitory effects on miR-29b expression; thus miR-29b can freely target Sp1 mRNA for translation inhibition. Low Sp1 levels leads to reduction in FLT3 expression and activity and as a result reduced cell survival and growth.